Eloralintide
ENLIGHTEN-3
Eli Lilly · Phase 3 · Recruiting · Enrollment 800
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Eloralintide (YSA1) | n/r | n/r | n/r | n/r | n/r |
| Placebo (YSA1) | n/r | n/r | n/r | n/r | n/r |
| Eloralintide (YSA2) | n/r | n/r | n/r | n/r | n/r |
| Placebo (YSA2) | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.